A new Chinese‑developed bispecific antibody‑drug conjugate, Iza‑bren, has delivered a stunning 100 % overall response rate in patients with aggressive triple‑negative breast cancer. By linking a cleavable tetrapeptide bridge to a topoisomerase I inhibitor, the therapy attacks tumors more powerfully and for longer periods, offering a realistic chance of long‑term survival for those whose disease was once deemed untreatable. The 2025 ESMO meeting highlighted a broader wave of Chinese innovation reshaping breast‑cancer care. CDK4/6 inhibitors such as abemaciclib and ribociclib now show durable benefits even in early‑stage, node‑negative patients, cutting death risk by up to 16 % and pushing five‑year disease‑free survival past 85 %. Meanwhile, China’s first‑in‑class TROP2 ADC, Lu Kang Sha Tu Zhu, more than doubled progression‑free survival (8.3 vs 4.1 months) in a trial that included HER2‑zero and HER2‑low tumors, proving effective after CDK4/6 resistance. Together, these advances signal a shift from one‑size‑fits‑all chemotherapy to precision, multi‑target regimens. Doctors will need new guidelines for selecting patients and managing side effects, but the payoff could be a new era where advanced breast cancer becomes a manageable, long‑term condition rather than a death sentence.
Read moreAt the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Chinese researchers unveiled a series of breakthrough treatments that could change the outlook for breast‑cancer patients worldwide. For hormone‑receptor‑positive tumors, the latest data on CDK4/6 inhibitors such as abemaciclib and ribociclib showed a clear survival benefit even in early‑stage disease, with five‑year disease‑free rates climbing above 80%. When tumors become resistant to these drugs, a new antibody‑drug conjugate (ADC) called sacituzumab govitecan, developed in China, doubled the time patients lived without disease progression compared with standard chemotherapy, and worked regardless of HER2 status. Perhaps the most striking advance came from a bispecific ADC targeting both EGFR and HER3, which achieved a 100% response rate in early trials for the aggressive triple‑negative subtype. Together, these innovations move breast‑cancer therapy from a one‑size‑fits‑all approach toward precise, multi‑targeted strategies. Doctors will need to learn new guidelines for selecting patients and managing side effects, but patients now have realistic chances of long‑term survival where few options existed before. The ESMO president hailed 2025 as the year Chinese breast‑cancer research entered its “coming‑of‑age,” reshaping global treatment standards.
Read moreResearchers have issued fresh guidance on how to define dose‑limiting toxicity (DLT) in first‑in‑human CAR‑T studies, aiming to make early trials safer and more consistent. The recommendations stress clear criteria for severe adverse events, standardized monitoring windows, and transparent reporting to help regulators and sponsors compare results across programs. At the same time, a wave of innovative CAR‑T advances is reshaping the field. Yale scientists introduced an IDR‑CAR fusion protein that lets engineered T cells spot and kill cancer cells with very low antigen levels, showing strong results in lab dishes and animal models. In China, a peripheral‑blood‑derived TIL‑like cell therapy (ScTIL) boosted overall survival five‑fold for patients with advanced biliary‑tract cancer, a finding published in Cell Reports Medicine. Other highlights include ultrasound‑triggered CAR‑T that locally switches on CD19 in solid tumors, an IL‑10‑producing CD19 CAR‑T showing promise in relapsed B‑ALL, and the first randomized Phase 2 trial of CLDN18.2‑CAR‑T (satri‑cel) that extended progression‑free survival in gastric cancer. Cutting‑edge CRISPR knock‑in strategies now embed therapeutic genes into tumor‑specific loci, while reviews stress the importance of leukapheresis quality and cryopreservation for reliable autologous CAR‑T manufacturing. Together, these developments point to safer trials and more effective, versatile cell‑based cancer treatments.
Read more